{"publication_id":"04a4e243-1f41-43e8-9394-cf52f62997db","traces":[{"claim_id":"claim_1","claim":"This paper synthesizes evidence on metformin treatment effects across 56 accepted source papers and 3357 high-confidence extracted claims.","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_2","claim":"The evidence profile contains 6 direct clinical sources, 27 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 484 cross-study disagreements across the evidence base.","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_3","claim":"Positive study-level signals are summarized in the cardiometabolic and contextual adjacent evidence outcome classes, null signals in the contextual adjacent evidence, cardiometabolic, dosing and pharmacokinetics outcome classes, and negative signals in the cardiometabolic, contextual adjacent evidence, safety and comorbidity outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_4","claim":"The conclusion is that metformin treatment effects remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_5","claim":"This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-metformin_treatment_effects-v06-DAILY-2026-06-12T04-21-22Z-R2`.","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_6","claim":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_7","claim":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_8","claim":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, cognitive, contextual adjacent evidence, dosing and pharmacokinetics, immune and inflammation, longevity, safety, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_9","claim":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_10","claim":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_11","claim":"| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_12","claim":"| Contextual Adjacent Evidence | n=27; claims=1160 | no extracted directional signal in 18/27 sources | 1 direct; 16 indirect; 10 review | limited corpus depth in this outcome class |","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_13","claim":"This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_14","claim":"27 included sources were assigned to this outcome class. Directional coding: negative=1, null=18, positive=1, unclear=7. Directness coding: direct=1, indirect=16, review=10.","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_15","claim":"18 included sources were assigned to this outcome class. Directional coding: mixed=3, negative=4, null=7, positive=2, unclear=2. Directness coding: direct=5, indirect=6, review=7.","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_16","claim":"3 included sources were assigned to this outcome class. Directional coding: null=2, unclear=1. Directness coding: indirect=1, review=2.","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_17","claim":"3 included sources were assigned to this outcome class. Directional coding: negative=1, null=2. Directness coding: indirect=2, review=1.","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_18","claim":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: review=1.","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_19","claim":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_20","claim":"Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_21","claim":"The curated corpus is dominated by sources in which metformin is used as background or add-on therapy rather than as the randomized intervention under test, and this constrains what the headline conclusions can support. In Hong 2026, Seo 2026, Lee 2026, Lim 2026, Zaveri 2026, Mohan 2026, and Kim 2026, metformin is the comparator floor or backbone to which a new agent (pioglitazone 30 mg, lobeglitazone 0.5 mg, empagliflozin, sitagliptin+empagliflozin FDC, sitagliptin+glimepiride FDC, glimepiride+voglibose, or a fourth oral drug) is added. Across those records, between-group p-values are routinely <0.0001 or <0.001, but the contrast is rarely metformin-vs-placebo. Conclusions about metformin monotherapy efficacy and durability therefore rest on indirect inference, not on within-corpus metformin-vs-placebo arms. The single RCT that randomizes metformin vs another glucose-lowering agent head-to-head in this bundle is Lim 2026b (empagliflozin vs metformin in drug-naïve T2D, HbA1c change −0.78% on metformin), and that single source is the only one that anchors a direct monotherapy estimate in the corpus.","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_22","claim":"For metformin treatment effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_23","claim":"This synthesis maps 56 included sources on Metformin Treatment Effects across 9 outcome classes and 484 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_24","claim":"Across 56 curated reference papers, the evidence base for Metformin Treatment Effects shows a context-dependent profile. Positive signals appear in: cardiometabolic, contextual other. Negative signals appear in: cardiometabolic, contextual other. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Metformin Treatment Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_25","claim":"Prior reviews in the corpus (Malik 2026, Hamsho 2026, Zhang 2026, Lim 2026b, Kao 2026) emphasize convergent signals on Metformin Treatment Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_26","claim":"| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_27","claim":"| cardiometabolic | 5 | 13 | mixed, negative, null, positive, unclear | conflict-resolution gap |","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_28","claim":"| dosing and pharmacokinetics | 0 | 3 | null, unclear | direct interventional hard-endpoint gap |","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_29","claim":"| safety and comorbidity | 0 | 3 | negative, null | direct interventional hard-endpoint gap |","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]},{"claim_id":"claim_30","claim":"| skeletal, fracture, and bone | 0 | 1 | null | direct interventional hard-endpoint gap |","candidate_sources":[{"study":"GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetes","doi":"10.1371/journal.pone.0337107","url":"https://doi.org/10.1371/journal.pone.0337107"},{"study":"Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial","doi":"10.4093/dmj.2024.0696","url":"https://doi.org/10.4093/dmj.2024.0696"},{"study":"HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin","doi":"10.1001/jamanetworkopen.2026.15622","url":"https://doi.org/10.1001/jamanetworkopen.2026.15622"},{"study":"Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial","doi":"10.1111/dom.70386","url":"https://doi.org/10.1111/dom.70386"},{"study":"Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial","doi":"10.1111/dom.70257","url":"https://doi.org/10.1111/dom.70257"}]}]}